L&T Technology Services has launched an NVIDIA-enabled digital twin platform designed to advance respiratory imaging, diagnosis and clinical decision-making through AI-driven precision.
The new platform creates comprehensive digital replicas of the human respiratory system using CT scans integrated with advanced segmentation, artificial intelligence and deep-learning models.
It maps airways, lung lobes, blood vessels and potential abnormalities, helping clinicians analyse disease patterns with greater clarity. Powered by NVIDIA technologies, the system delivers real-time visualisation with capabilities that support diagnosis, monitoring and procedural planning for conditions like COPD and lung cancer.
The company highlighted how the solution is built to assist clinicians with immersive, high-precision simulations.
The platform utilises NVIDIA MONAI for medical imaging workflows and NVIDIA TensorRT for high-speed inference, enabling smoother rendering and precise modelling of respiratory structures. Interactive 3D visualisation supports multiple clinical tasks, from identifying lesions to simulating potential treatment approaches.
As per exchange filings, NVIDIA’s David Niewolny highlighted the importance of the joint effort, saying “working with LTTS to accelerate AI-enabled medical technology demonstrates how NVIDIA is empowering the healthcare industry with accelerated computing and AI innovation.”
Read More: Best Artificial Intelligence Stocks for December 2025: Persistent, Saksoft, and More Based on 5-Year CAGR!
As of December 1, 2025, at 11:35 AM, L&T Technology Services Ltd share price is trading at ₹4,420.20 per share, reflecting a decline of 0.45% from the previous closing price. Over the past month, the stock has gained by 7.30%.
By combining LTTS’ engineering expertise with NVIDIA’s AI acceleration, the digital twin platform delivers a new level of imaging depth and analytical capability. The solution aims to strengthen clinical confidence, improve interpretation of complex respiratory conditions and support better patient outcomes.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Dec 1, 2025, 1:35 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
EN